Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TRAF3 loss protects glioblastoma cells from lipid peroxidation and immune elimination via dysregulated lipid metabolism
Yu Zeng, … , Ye Song, Aidong Zhou
Yu Zeng, … , Ye Song, Aidong Zhou
Published February 11, 2025
Citation Information: J Clin Invest. 2025;135(7):e178550. https://doi.org/10.1172/JCI178550.
View: Text | PDF
Research Article Cell biology Metabolism

TRAF3 loss protects glioblastoma cells from lipid peroxidation and immune elimination via dysregulated lipid metabolism

  • Text
  • PDF
Abstract

Glioblastoma (GBM) is a highly aggressive form of brain tumor characterized by dysregulated metabolism. Increased fatty acid oxidation (FAO) protects tumor cells from lipid peroxidation–induced cell death, although the precise mechanisms involved remain unclear. Here, we report that loss of TNF receptor–associated factor 3 (TRAF3) in GBM critically regulated lipid peroxidation and tumorigenesis by controlling the oxidation of polyunsaturated fatty acids (PUFAs). TRAF3 was frequently repressed in GBM due to promoter hypermethylation. TRAF3 interacted with enoyl-CoA hydratase 1 (ECH1), an enzyme that catalyzes the isomerization of unsaturated FAs (UFAs) and mediates K63-linked ubiquitination of ECH1 at Lys214. ECH1 ubiquitination impeded TOMM20-dependent mitochondrial translocation of ECH1, which otherwise promoted the oxidation of UFAs, preferentially the PUFAs, and limited lipid peroxidation. Overexpression of TRAF3 enhanced the sensitivity of GBM to ferroptosis and anti–programmed death–ligand 1 (anti–PD-L1) immunotherapy in mice. Thus, the TRAF3/ECH1 axis played a key role in the metabolism of PUFAs and was crucial for lipid peroxidation damage and immune elimination in GBM.

Authors

Yu Zeng, Liqian Zhao, Kunlin Zeng, Ziling Zhan, Zhengming Zhan, Shangbiao Li, Hongchao Zhan, Peng Chai, Cheng Xie, Shengfeng Ding, Yuxin Xie, Li Wang, Cuiying Li, Xiaoxia Chen, Daogang Guan, Enguang Bi, Jianyou Liao, Fan Deng, Xiaochun Bai, Ye Song, Aidong Zhou

×

Figure 3

TRAF3 interacts with ECH1 and promotes K63-linked ubiquitination of ECH1 at Lys214.

Options: View larger image (or click on image) Download as PowerPoint
TRAF3 interacts with ECH1 and promotes K63-linked ubiquitination of ECH1...
(A) U87MG cells were transfected with Flag-TRAF3, and cell lysates were incubated with an anti–Flag-Tag antibody. The immunoprecipitated protein complexes were resolved by SDS-PAGE, and specific protein bands, identified by silver staining, were subjected to MS analysis. The black arrowhead indicates the TRAF3 band, and the white arrowhead indicates the ECH1 band identified by tandem MS/MS. IgH and IgL indicate the IgG heavy chain and light chain, respectively. H, heavy chain; L, light chain. (B) Coimmunoprecipitation assays demonstrate the reciprocal interaction between TRAF3 and ECH1 in GBM0709 and GBM0108 cells after treatment with 5-Aza. (C) Myc-tagged full-length ECH1 or deletion mutants were cotransfected with Flag-TRAF3 into HEK293T cells. Cell lysates were immunoprecipitated using an anti-Myc antibody, and the immunoprecipitates were analyzed by immunoblotting (IB) using the indicated antibodies. (D) HEK293T cells were transfected with the Myc-ECH1, Flag-TRAF3, and HA-Ub plasmids. The cell lysates were incubated with an anti–Myc-tag antibody and then subjected to immunoblotting. (E) GBM0108 cells were transfected with TRAF3 siRNA and HA-ubiquitin (HA-Ub), and then were treated with 5-Aza. The cell lysates were immunoprecipitated with an anti-Myc antibody and then analyzed by immunoblotting. (F) HEK293T cells were transfected with the indicated plasmids and then incubated with an anti–Myc-tag antibody. The resultant immunoprecipitates were analyzed by immunoblotting. (G) The binding mode between TRAF3 and ECH1 was predicted by the HDOCK server. The protein tertiary structures for TRAF3 and ECH1 were retrieved from the Alphafold database. Yellow dashed lines indicate possible interactions, and residues highlighted in red indicate potential residues mediating protein-protein interactions. The interatomic distances between TRAF3 and ECH1 are indicated. (H) HEK293T cells were transfected with Flag-TRAF3, HA-Ub-K63, and Myc-ECH1 or each of the ECH1 mutants (K214R or K276R). The cell lysates were immunoprecipitated with an anti-Myc antibody and then analyzed by immunoblotting. (I) In vitro ubiquitination assay using the indicated purified proteins in the presence of E1 and E2 enzymes and Mg2+-ATP (10 mM) in the ubiquitination reaction buffer. The reaction mixtures were purified by Ni-NTA beads, and the eluted proteins were analyzed by immunoblotting. M, molecular weight; K, kDa.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts